Rilotumumab is an investigational, fully human, monoclonal antibody 
immunoglobulin G2 against hepatocyte growth factor (HGF) that blocks the binding 
of HGF to its receptor MET and has shown trends toward improved survival in a 
phase 2 clinical trial in gastric cancer. To characterize rilotumumab 
pharmacokinetics in patients with cancer and to identify factors affecting the 
pharmacokinetics, rilotumumab concentration data from seven clinical trials were 
analyzed with a nonlinear mixed-effect model. We found that rilotumumab 
exhibited linear and time-invariant kinetics over a dose range of 0.5-20 mg/kg. 
Typical systemic clearance and central volume of distribution were 0.184 L/day 
and 3.56 L, respectively. Body weight is the most significant covariate, and 
sex, cancer type, coadministration of chemotherapeutics, baseline plasma HGF and 
tumor MET levels, and renal and hepatic functions did not have an effect on 
rilotumumab pharmacokinetics. The concentration-time profiles for the 
rilotumumab clinical regimens were projected well with the model.